Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Applied Molecular Evolution Inc.

Division of Eli Lilly & Co.
www.amevolution.com

Latest From Applied Molecular Evolution Inc.

BIO Notebook, Day 3: Lilly Expands R&D Site, Sigilon Raises Cash And CytomX Talks Deal Strategy

Day three at the BIO International Convention included an off-site visit to Lilly's newly expanded R&D site as well as conversations with Sigilon about the $23m Series A venture funding round it announced that morning and with CytomX about its dealmaking strategy.

Research and Development Strategies Business Strategies

Lilly Investing In Future, But Staying Out Of The Biotech 'Bubble'

Firm exceeds expectations in the second quarter, but is content to rely on in-house prospects for growth and take a measured approach to deal-making rather than jumping into the fray for the “hot property of the moment.”

BioPharmaceutical Deals

The Large Molecule Future

In an extraordinary series of deals, Pharma has embraced early-stage large-molecule technology, reflecting both the surging value of biologics and the severity of pipeline anemia. But many observers are skeptical the less experienced Big Pharmas can buy themselves into a brand new business with very different requirements. For start-ups, however, the news is very good--they now have two clear and viable pathways to creating shareholder value: acquisition and alliance.
BioPharmaceutical Strategy

Trade Sales Trump IPOs, Even for Platforms

Europe's summertime flurry of private biotech sell-offs points to growing pragmatism among management and VCs, and still-poor valuations on the public markets. Firms which haven't already considered the trade sale opportunity should do so--even early-stage, pre-product platform groups.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ixsys Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Eli Lilly & Co.
  • Senior Management
  • William D Huse, MD, PhD, CEO
    Lawrence E Bloch, MD, CFO
    Jeffery D Watkins, PhD, CSO
    Keith Manchester, MD, VP, Bus. Dev.
  • Contact Info
  • Applied Molecular Evolution Inc.
    Phone: (858) 597-4990
    3550 Dunhill St.
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register